To start with, when we saw it was a pandemic, there were two components. The first was that we needed to find the best possible way to address this pandemic by producing vaccines as quickly and as safely as possible. To do so, we made sure that we put all our R and D resources into having our researchers, in collaboration with BioNTech, actually discover and then do the research and development, testing, manufacturing and distribution of the vaccines. Once you have that solution in your hands, you want to deploy it as widely as possible. As such, we were reaching out to all the countries in the world to make sure they would have an opportunity to sign an agreement with Pfizer.
To be very transparent, some raised their hands right away. Others decided to wait a bit, despite our tier pricing model. As such, we were offering our vaccines to every country in the world, including COVAX countries—with COVAX, of course—to make sure they would have access to it. However, as I said, some countries decided to sign agreements with Pfizer right away to—